Aurobindo Irbesartan $2 Million Settlement for Nitrosamine Contamination Claims
The Aurobindo Irbesartan $2 Million Settlement for Nitrosamine Contamination Claims settlement offers $2M in total, with individual payouts of $11 to $129 to eligible claimants who claimant is an individual located in the united states, its territories, or possessions.. The deadline to file is June 2, 2026. Proof of purchase is not required.
Deadline: June 2, 2026
Total amount allocated for all claims
Estimated amount per eligible claim
No proof of purchase needed — anyone eligible can file a claim
No documentation is required for claims at or below $10.71 per 30-day supply and $128.52 total, though the administrator may request proof to verify. Documentation is required for amounts above those thresholds, including pharmacy receipts and/or pharmacy records showing the claimant’s qualifying out-of-pocket purchases and supporting the higher claimed amounts.
Settlement Summary
Irbesartan is a widely prescribed blood-pressure medicine in a class of drugs called ARBs. This lawsuit stems from concerns that certain batches of irbesartan made by Aurobindo may have contained trace “nitrosamine” impurities—specifically N-nitrosodimethylamine (NDMA) and NDEA—substances that regulators have flagged as probable human carcinogens at sufficiently high or prolonged exposure. Because patients and health systems rely on these drugs for long-term treatment, even small contamination risks can trigger serious public health worries, prompting regulators and industry to investigate and reform manufacturing controls. The case is part of a broader, coordinated set of drug contamination claims brought in multidistrict litigation involving valsartan, losartan, and irbesartan products. The Aurobindo defendants agreed to a $2 million settlement to resolve allegations that their irbesartan products—manufactured, supplied, distributed, marketed, or sold using specific Aurobindo synthesis routes—violated state consumer-protection laws by putting potentially contaminated medications into commerce. The significance of the settlement is that it offers cash payments to eligible U.S. consumers who bought qualifying Aurobindo irbesartan retail prescriptions between Jan. 1, 2016, and the present, with awards calculated primarily by the amount of qualifying medication purchased (and higher amounts available with proof of higher out-of-pocket costs). Broader implications include heightened scrutiny across the generic and branded drug industries over nitrosamine risks, stronger expectations for process controls and impurity monitoring, and the continuing ripple effects of similar contamination settlements—such as the parallel Hetero valsartan and Vivimed losartan resolutions—within the same larger litigation. In the background, industry participants operate under drug-safety frameworks overseen by regulators like the FDA, including requirements for impurity control, quality systems, and risk-based manufacturing oversight, and settlements like this underscore how supply-chain and synthesis changes can become central legal and compliance issues when contamination concerns arise.
Entities Involved
Related Topics
Eligibility Requirements
- Claimant is an individual located in the United States, its territories, or possessions.
- Claimant paid any amount for retail purchases of Aurobindo Irbesartan finished drug formulations.
- The purchased medication was manufactured using Aurobindo’s specified irbesartan active pharmaceutical ingredient and produced using Aurobindo’s IC Route of Synthesis.
- Purchases occurred between Jan. 1, 2016, and the present.
- Payment must be out-of-pocket by the claimant (including copays/coinsurance or full retail price).
- Purchases made on behalf of someone else (e.g., a dependent) may qualify if the claimant paid for the medication.
- The medication qualifies under the settlement’s listed National Drug Code (NDC) numbers.
- Pharmacy benefit managers (PBMs) are not eligible class members.
Featured Investigations
Stay Updated
Subscribe to our newsletter for the latest settlement updates and news.
Important Notice About Filing Claims
Submitting false information in a settlement claim is considered perjury and will result in your claim being rejected. Fraudulent claims harm legitimate class members and may result in legal consequences.
If you are unsure about your eligibility for this settlement, please visit the official settlement administrator’s website using the link provided above. Review the eligibility criteria carefully before submitting a claim.
Class Action Champion is an independent information resource and is not affiliated with any settlement administrator, law firm, or court. We provide settlement information as a service to help connect eligible class members with legitimate settlements.